Skip to main content
Jon Cuthbert Profile pIcture
Jon Cuthbert

Jon Cuthbert

GrafaFounder & COO

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.

Articles by Jon Cuthbert

Grafa
Health

Ocugen reports positive 12-Month phase 2 ArMaDa results for geographic atrophy

Ocugen (NASDAQ:OCGN) today announced positive 12-month results from its Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV-hRORA), a modifier gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (dAMD).

Read more: Ocugen reports positive 12-Month phase 2 ArMaDa results for geographic atrophy
Grafa
Health

Karyopharm reports mixed Phase 3 SENTRY results in frontline myelofibrosis

Karyopharm Therapeutics (NASDAQ:KPTI) today announced topline results from its global Phase 3 SENTRY clinical trial (n=353) evaluating the XPO1 inhibitor selinexor in combination with ruxolitinib (Jakafi®) for the frontline treatment of patients with myelofibrosis.

Read more: Karyopharm reports mixed Phase 3 SENTRY results in frontline myelofibrosis
Grafa
Health

Radiopharm Theranostics reports 90% concordance in Phase 2b brain metastases imaging trial

Radiopharm Theranostics (NASDAQ:RADX) today released a highly encouraging second interim data update from its ongoing U.S. Phase 2b clinical trial evaluating RAD 101, a novel FASN-targeting small-molecule imaging agent.

Read more: Radiopharm Theranostics reports 90% concordance in Phase 2b brain metastases imaging trial
Grafa

Regeneron and Sanofi secure historic seventh Japanese indication for Dupixent in bullous pemphigoid

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP) whose disease is not adequately controlled by existing therapies.

Read more: Regeneron and Sanofi secure historic seventh Japanese indication for Dupixent in bullous pemphigoid